Novo Nordisk A/S is prepared for potential tariffs from US President Donald Trump, the Danish drugmaker’s chief executive ...

We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data ...

Donald Trump 's renewed push to take control of Greenland is setting off a high-stakes showdown with Denmark, a small country ...

J&J, AstraZeneca, Novo Nordisk and Roche are among the companies that might take a hit from the soon-to-be-enacted fees, ...

As expected, the tariffs were announced, 25% from Mexico and Canada ... Cramer mentioned that he expects Novo Nordisk A/S (NYSE:NVO) to forecast a good 2025 like its peer, Eli Lilly.

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Novo Nordisk (NVO), the maker of the popular GLP-1 medications Wegovy and Ozempic, said potential tariffs on Europe imposed ...

Robert F. Kennedy Jr.’s HHS nomination moves to a full Senate vote; Donald Trump’s tariff war sparks China-related concerns ...

Stocks to Buy or Sell. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks to buy and sell highlighted in Jim Cramer’s latest calls. Jim ...